Delayed
Japan Exchange
07:00:00 02/05/2024 BST
|
5-day change
|
1st Jan Change
|
2,280
JPY
|
-0.11%
|
|
-4.86%
|
-14.38%
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
156,406
|
129,800
|
211,857
|
165,227
|
151,722
|
129,576
|
-
|
-
|
Enterprise Value (EV)
1 |
172,623
|
164,967
|
249,351
|
191,736
|
184,700
|
168,141
|
165,223
|
162,022
|
P/E ratio
|
24.5
x
|
-251
x
|
12.1
x
|
5.59
x
|
9.68
x
|
-25.9
x
|
25.2
x
|
17.9
x
|
Yield
|
4.73%
|
5.71%
|
3.88%
|
4.3%
|
4.69%
|
5.48%
|
4.83%
|
5.29%
|
Capitalization / Revenue
|
0.86
x
|
0.69
x
|
0.95
x
|
0.61
x
|
0.58
x
|
0.55
x
|
0.53
x
|
0.51
x
|
EV / Revenue
|
0.95
x
|
0.87
x
|
1.12
x
|
0.7
x
|
0.71
x
|
0.71
x
|
0.68
x
|
0.64
x
|
EV / EBITDA
|
7.09
x
|
7.76
x
|
6.58
x
|
2.94
x
|
4.29
x
|
8.51
x
|
5.45
x
|
4.92
x
|
EV / FCF
|
-113
x
|
-45.8
x
|
34.1
x
|
7.87
x
|
62.6
x
|
44
x
|
13.4
x
|
11.7
x
|
FCF Yield
|
-0.88%
|
-2.18%
|
2.93%
|
12.7%
|
1.6%
|
2.27%
|
7.44%
|
8.55%
|
Price to Book
|
1.39
x
|
1.26
x
|
1.84
x
|
1.18
x
|
1.01
x
|
0.92
x
|
0.93
x
|
0.93
x
|
Nbr of stocks (in thousands)
|
56,958
|
56,980
|
57,027
|
56,877
|
56,910
|
56,819
|
-
|
-
|
Reference price
2 |
2,746
|
2,278
|
3,715
|
2,905
|
2,666
|
2,280
|
2,280
|
2,280
|
Announcement Date
|
14/05/19
|
13/05/20
|
14/05/21
|
12/05/22
|
12/05/23
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
181,415
|
188,712
|
223,016
|
272,944
|
260,908
|
236,950
|
244,663
|
254,200
|
EBITDA
1 |
24,352
|
21,269
|
37,886
|
65,116
|
43,075
|
19,755
|
30,325
|
32,913
|
EBIT
1 |
14,648
|
9,939
|
25,392
|
50,490
|
23,381
|
-1,021
|
8,450
|
12,295
|
Operating Margin
|
8.07%
|
5.27%
|
11.39%
|
18.5%
|
8.96%
|
-0.43%
|
3.45%
|
4.84%
|
Earnings before Tax (EBT)
1 |
11,375
|
6,113
|
20,823
|
41,323
|
22,907
|
-5,350
|
4,150
|
9,450
|
Net income
1 |
6,386
|
-516
|
17,468
|
29,599
|
15,676
|
-5,000
|
5,155
|
7,780
|
Net margin
|
3.52%
|
-0.27%
|
7.83%
|
10.84%
|
6.01%
|
-2.11%
|
2.11%
|
3.06%
|
EPS
2 |
111.9
|
-9.060
|
306.4
|
519.6
|
275.5
|
-87.95
|
90.66
|
127.6
|
Free Cash Flow
1 |
-1,524
|
-3,604
|
7,315
|
24,367
|
2,952
|
3,822
|
12,294
|
13,861
|
FCF margin
|
-0.84%
|
-1.91%
|
3.28%
|
8.93%
|
1.13%
|
1.61%
|
5.03%
|
5.45%
|
FCF Conversion (EBITDA)
|
-
|
-
|
19.31%
|
37.42%
|
6.85%
|
19.35%
|
40.54%
|
42.11%
|
FCF Conversion (Net income)
|
-
|
-
|
41.88%
|
82.32%
|
18.83%
|
-
|
238.48%
|
178.16%
|
Dividend per Share
2 |
130.0
|
130.0
|
144.0
|
125.0
|
125.0
|
125.0
|
110.2
|
120.5
|
Announcement Date
|
14/05/19
|
13/05/20
|
14/05/21
|
12/05/22
|
12/05/23
|
-
|
-
|
-
|
Fiscal Period: March |
2020 S1
|
2021 S1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
93,480
|
98,566
|
70,247
|
133,739
|
64,142
|
75,063
|
65,331
|
68,750
|
134,081
|
66,882
|
59,945
|
56,620
|
59,923
|
116,543
|
60,968
|
59,439
|
59,200
|
59,900
|
60,500
|
59,400
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
13,855
|
-
|
11,242
|
4,947
|
-
|
5,270
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
5,758
|
8,146
|
14,724
|
26,951
|
9,220
|
14,319
|
8,580
|
9,104
|
17,684
|
5,966
|
-269
|
-1,711
|
142
|
-1,569
|
422
|
-553
|
1,300
|
1,500
|
1,900
|
1,100
|
Operating Margin
|
6.16%
|
8.26%
|
20.96%
|
20.15%
|
14.37%
|
19.08%
|
13.13%
|
13.24%
|
13.19%
|
8.92%
|
-0.45%
|
-3.02%
|
0.24%
|
-1.35%
|
0.69%
|
-0.93%
|
2.2%
|
2.5%
|
3.14%
|
1.85%
|
Earnings before Tax (EBT)
|
3,965
|
6,160
|
13,675
|
25,090
|
8,626
|
7,607
|
8,128
|
12,574
|
20,702
|
5,084
|
-2,879
|
-1,165
|
-425
|
-1,590
|
-1,646
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
2,544
|
5,102
|
11,176
|
19,519
|
5,999
|
4,081
|
5,587
|
9,966
|
15,553
|
3,236
|
-3,113
|
-1,120
|
-702
|
-1,822
|
-1,523
|
-1,655
|
700
|
900
|
800
|
800
|
Net margin
|
2.72%
|
5.18%
|
15.91%
|
14.59%
|
9.35%
|
5.44%
|
8.55%
|
14.5%
|
11.6%
|
4.84%
|
-5.19%
|
-1.98%
|
-1.17%
|
-1.56%
|
-2.5%
|
-2.78%
|
1.18%
|
1.5%
|
1.32%
|
1.35%
|
EPS
|
44.67
|
89.52
|
-
|
342.2
|
105.4
|
-
|
98.25
|
-
|
273.4
|
56.84
|
-
|
-19.67
|
-12.33
|
-32.00
|
-26.78
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
65.00
|
50.00
|
-
|
62.00
|
-
|
-
|
-
|
-
|
62.00
|
-
|
-
|
-
|
62.00
|
62.00
|
-
|
63.00
|
-
|
62.50
|
-
|
62.50
|
Announcement Date
|
11/11/19
|
10/11/20
|
09/11/21
|
09/11/21
|
08/02/22
|
12/05/22
|
09/08/22
|
09/11/22
|
09/11/22
|
08/02/23
|
12/05/23
|
08/08/23
|
09/11/23
|
09/11/23
|
09/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
16,217
|
35,167
|
37,494
|
26,509
|
32,978
|
38,565
|
35,647
|
32,446
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.6659
x
|
1.653
x
|
0.9897
x
|
0.4071
x
|
0.7656
x
|
1.952
x
|
1.175
x
|
0.9858
x
|
Free Cash Flow
1 |
-1,524
|
-3,604
|
7,315
|
24,367
|
2,952
|
3,822
|
12,294
|
13,861
|
ROE (net income / shareholders' equity)
|
5.7%
|
-0.5%
|
16%
|
23.2%
|
10.8%
|
-0.96%
|
3.6%
|
5.5%
|
ROA (Net income/ Total Assets)
|
6.11%
|
3.08%
|
10.8%
|
17.6%
|
7.53%
|
-1.45%
|
1.7%
|
3.6%
|
Assets
1 |
104,541
|
-16,779
|
161,984
|
168,317
|
208,151
|
344,828
|
303,253
|
216,111
|
Book Value Per Share
2 |
1,980
|
1,809
|
2,020
|
2,463
|
2,635
|
2,469
|
2,440
|
2,448
|
Cash Flow per Share
2 |
264.0
|
174.0
|
518.0
|
775.0
|
618.0
|
478.0
|
496.0
|
525.0
|
Capex
1 |
17,768
|
18,833
|
27,375
|
41,654
|
22,558
|
19,233
|
15,767
|
15,933
|
Capex / Sales
|
9.79%
|
9.98%
|
12.27%
|
15.26%
|
8.65%
|
8.12%
|
6.44%
|
6.27%
|
Announcement Date
|
14/05/19
|
13/05/20
|
14/05/21
|
12/05/22
|
12/05/23
|
-
|
-
|
-
|
Mean consensus UNDERPERFORM Last Close Price
2,280
JPY Average target price
2,542
JPY Spread / Average Target +11.47% Consensus |
1st Jan change
|
Capi.
|
---|
| -14.38% | 823M | | -19.14% | 8.22B | | +48.66% | 3.73B | | -8.06% | 2.46B | | -38.71% | 2.46B | | -8.84% | 2.36B | | -9.02% | 1.78B | | -19.29% | 1.52B | | -40.78% | 1.21B | | +8.32% | 1.12B |
Medical & Diagnostic Laboratories
|